Additional file 1: Table S1. Antibodies used for flow cytometric analysis of PBMC. Table S2. Tabular results for OLINK™ target 48-cytokine screening. Significance testing was performed using Wilcoxon’s paired rank-sum test
Markov Chain Monte Carlo simulation of probability variables corresponding to effectiveness and risk...
Table S9. Correlation between STAT phosphorylation and HLA-E, HLA-ABC, and HLA-DR expression in diff...
Table S1. Neurodegenerative and neuroinflammatory markers in CSF (and for NFL also in serum) over ti...
Process for selecting published studies used to estimate effectiveness and risk of non-serious adver...
Table S4. Comparison of levels of p38MAPK, Erk1/2, STAT1, and STAT6 between MS patients and controls...
Table S1. Comparison of levels of phosphorylated proteins between MS patients and controls in baseli...
List of DEGs characterizing SPMS untreated vs. RRMS untreated patients. (XLSX 21 kb
Histogram of the flow cytometry for healthy control (A), MOG-IgG-positive sera with a dilution of 1:...
Gating strategy for flow cytometric analysis of viable CD19+ B cells and CD4+ T cells in the blood. ...
Additional file 1: Table S1. Antibodies used for flow cytometryâbased minimal residual disease ass...
Histogram of the flow cytometry and geometric mean fluorescence (G-mean) ratio for healthy control a...
Table S3. Comparison of levels of phosphorylated proteins between MS patients and controls after in ...
Detailed search and data preparation methods. This file includes search strings, grey literature sea...
Multiple sclerosis patient characteristics. All multiple sclerosis patients had relapsing-remitting ...
Table S1. Table describing the hematological and serological profile of our patient with Alemtuzumab...
Markov Chain Monte Carlo simulation of probability variables corresponding to effectiveness and risk...
Table S9. Correlation between STAT phosphorylation and HLA-E, HLA-ABC, and HLA-DR expression in diff...
Table S1. Neurodegenerative and neuroinflammatory markers in CSF (and for NFL also in serum) over ti...
Process for selecting published studies used to estimate effectiveness and risk of non-serious adver...
Table S4. Comparison of levels of p38MAPK, Erk1/2, STAT1, and STAT6 between MS patients and controls...
Table S1. Comparison of levels of phosphorylated proteins between MS patients and controls in baseli...
List of DEGs characterizing SPMS untreated vs. RRMS untreated patients. (XLSX 21 kb
Histogram of the flow cytometry for healthy control (A), MOG-IgG-positive sera with a dilution of 1:...
Gating strategy for flow cytometric analysis of viable CD19+ B cells and CD4+ T cells in the blood. ...
Additional file 1: Table S1. Antibodies used for flow cytometryâbased minimal residual disease ass...
Histogram of the flow cytometry and geometric mean fluorescence (G-mean) ratio for healthy control a...
Table S3. Comparison of levels of phosphorylated proteins between MS patients and controls after in ...
Detailed search and data preparation methods. This file includes search strings, grey literature sea...
Multiple sclerosis patient characteristics. All multiple sclerosis patients had relapsing-remitting ...
Table S1. Table describing the hematological and serological profile of our patient with Alemtuzumab...
Markov Chain Monte Carlo simulation of probability variables corresponding to effectiveness and risk...
Table S9. Correlation between STAT phosphorylation and HLA-E, HLA-ABC, and HLA-DR expression in diff...
Table S1. Neurodegenerative and neuroinflammatory markers in CSF (and for NFL also in serum) over ti...